Pictet Asset Management (Switzerland)’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Pictet Asset Management (Switzerland)’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-4,739	Closed	-$215K	–	2045
2022 Q4	$215K	Sell	4,739 -236,241	-98%	-$15.3M	﹤0.01%	1698
2022 Q3	$16.8M	Buy	240,980 +2,033	+0.9%	+$150K	0.03%	465
2022 Q2	$16M	Sell	238,947 -140,129	-37%	-$8.91M	0.02%	498
2022 Q1	$31.2M	Buy	379,076 +78,807	+26%	+$8.06M	0.04%	398
2021 Q4	$44M	Buy	300,269 +50,164	+20%	+$7.79M	0.04%	364
2021 Q3	$44.2M	Buy	+250,105	New	+$40.2M	0.05%	357

Other funds holding MRTX

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Pictet Asset Management (Switzerland)'s MRTX Position: Q1 2023 in Review

Pictet Asset Management (Switzerland) sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2023, closing a stake of 4,739 shares — an estimated $215K sold.

Pictet Asset Management (Switzerland) first reported a position in MRTX in Q3 2021 and held it in 6 quarters. The position peaked at $44.2M in Q3 2021. 221 funds tracked by Wall St. Rank hold MRTX as of Q1 2023.

Pictet Asset Management (Switzerland) reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Pictet Asset Management (Switzerland) sold 4,739 Mirati Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $215K.
Pictet Asset Management (Switzerland) first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2021 and held it in 6 quarters.
Pictet Asset Management (Switzerland)'s Mirati Therapeutics, Inc. Common Stock position peaked at $44.2M in Q3 2021.
221 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Pictet Asset Management (Switzerland)'s 13F filing for Q1 2023, filed 10 May 2023.